Back

Investigational randomized controlled trial of patients with inoperable chronic thromboembolic pulmonary hypertension treated with riociguat vs selexipag

1 September 2025 (08:15 - 09:00)
Organised by: Logo
Congress Presentation Part of: Pulmonary arterial hypertension: general (3) Pulmonary Hypertension ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Assistant Professor Yoshihisa Nakano

Nagoya University Hospital, Nagoya (Japan)

6 More presentations in this session

Presentation thumbnail
SGLT2i downregulate the activin/inhibin and miR-1306-5p signaling pathways in patients with HFrEF and associated pulmonary hypertension: a prospective intervention study
Doctor M. Alberti (Pisa, IT)
Abstract Slides Video
Presentation thumbnail
Insulin resistance indices are associated with the presence and outcomes of pulmonary hypertension due to left heart failure
Doctor R. Quan (Beijing, CN)
Abstract Slides Video
Presentation thumbnail
Left atrial V-wave as a potential new pathophysiological trigger of pulmonary hypertension
Doctor F. Bauer (Le Kremlin-Bicetre, FR)
Abstract Slides Video
Presentation thumbnail
Early CMR-derived markers of right ventricular involvement in combined post- and pre-capillary pulmonary hypertension
Doctor C. Perez Garcia (Madrid, ES)
Abstract Slides Video
Presentation thumbnail
Mapping right ventricular adaptation in pulmonary arterial hypertension: insights from a six-phenotype model
Doctor A. Lescano (Gran Buenos Aires, AR)
Abstract Slides Video

Access the full session

Session thumbnail
Pulmonary arterial hypertension: general (3)

The Event

Event poster

ESC Congress 2025

1 September 2025 08:15 CET
You may be interested in
thumbnail
Congress Presentation
Efficacy and tolerability of triple sequential combination therapies with selexipag in patients with pulmonary arterial hypertension : insights from a single-centre study
thumbnail
Congress Presentation
Switching sildenafil to riociguat in chronic thromboembolic pulmonary hypertension after balloon pulmonary angioplasty - the S2R study
thumbnail
Congress Presentation
Safety and efficacy of macitentan and riociguat upfront combination therapy in patients with idiopathic pulmonary arterial hypertension at intermediate risk.

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources